News Headlines Article

Alzheimer’s Drug Fails Its First Big Clinical Trial
New York Times

The most closely watched experimental treatment for Alzheimer’s disease proved ineffective in its first large clinical trial, dealing a blow to the field, to a theory about the cause of the disease, and to the three companies behind the drug. Pfizer, which is one of those companies, announced late Monday that the drug, bapineuzumab, did not improve either cognition or daily functioning of patients compared to a placebo in the Phase 3 trial.